摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

20-hydroxy-eicosanoic acid methyl ester | 37477-29-5

中文名称
——
中文别名
——
英文名称
20-hydroxy-eicosanoic acid methyl ester
英文别名
ω-Oxy-arachinsaeure-methylester;20-Hydroxy-eicosansaeure-methylester;methyl 20-hydroxyeicosanoate;methyl 20-hydroxyicosanoate
20-hydroxy-eicosanoic acid methyl ester化学式
CAS
37477-29-5
化学式
C21H42O3
mdl
——
分子量
342.563
InChiKey
OCCHBWCFXPQLRX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    8
  • 重原子数:
    24
  • 可旋转键数:
    20
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.95
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    20-hydroxy-eicosanoic acid methyl ester对甲苯磺酰氯吡啶 作用下, 以 二氯甲烷 为溶剂, 以91%的产率得到methyl 20-tosyleicosanoate
    参考文献:
    名称:
    Long chain carboxylic acid maleimides
    摘要:
    提供了以下一般式(I)所表示的新型超氧化物歧化酶衍生物:##STR1## 其中[SOD]是去除两个巯基团而得到的超氧化物歧化酶残基,W是一个二价的长链烃基残基,其可以选择性地被一个或多个分别从氧原子、硫原子和-N(R)-(R为低碳基)的群组中选择的基团所中断。这些SOD衍生物保留了未经改性的SOD的大部分酶活性,并且比未经改性的SOD具有更长的血浆半衰期。它们对于治疗由活性氧物种引起的各种疾病是有效的。此外,还提供了化学修饰剂来制备上述SOD衍生物。
    公开号:
    US05360914A1
  • 作为产物:
    参考文献:
    名称:
    RICHE, F.;MATHIEU, J. -P.;VINCENS, M.;BARDY, A.;COMET, M.;VIDAL, M., BULL. SOC. CHIM. FR., 1984, N 1-2, 49-55
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • 20-HETE antagonists and agonists
    申请人:——
    公开号:US20020049244A1
    公开(公告)日:2002-04-25
    20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    20-HETE激动剂和拮抗剂以及其治疗应用已被披露。在本发明的一种优选形式中,20-HETE激动剂被选自包括21-羟基油酸-5(Z), 8(Z),11(Z),14(Z)-四烯酸,20-羟基二十碳-5(Z),14(Z)-二烯酸和20-,21-二甲基20-HETE的组中。优选的20-HETE拮抗剂包括5(S)-HETE,15(S)-HETE,19(S)-HETE,19-羟基十九酸-5(Z),8(Z),11(Z),14(Z)-四烯酸和20-羟基二十碳-6(Z),15(Z)-二烯酸。
  • GRAPHENE COMPOUND AND MANUFACTURING METHOD THEREOF, ELECTROLYTE, AND POWER STORAGE DEVICE
    申请人:SEMICONDUCTOR ENERGY LABORATORY CO., LTD.
    公开号:US20180108944A1
    公开(公告)日:2018-04-19
    To provide a graphene compound having an insulating property and an affinity for lithium ions. To increase the molecular weight of a substituent included in a graphene compound. To provide a graphene compound including a chain group containing an ether bond or an ester bond. To provide a graphene compound including a substituent containing one or more branches. To provide a graphene compound including a substituent including at least one of an ester bond and an amide bond.
    提供具有绝缘性和对锂离子亲和性的石墨烯化合物。增加石墨烯化合物中包含的取代基的分子量。提供包含含有醚键或酯键的链基团的石墨烯化合物。提供包含含有一个或多个支链的取代基的石墨烯化合物。提供包含至少一种酯键和酰胺键的取代基的石墨烯化合物。
  • 20- Hete antagonists and agonists
    申请人:——
    公开号:US20020072534A1
    公开(公告)日:2002-06-13
    20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),ll(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    本发明揭示了20-HETE激动剂和拮抗剂及其治疗应用。在本发明的一种优选形式中,20-HETE激动剂选自以下组合:21-羟基十九碳五烯酸5(Z),8(Z),11(Z),14(Z)-四烯酸,20-羟基二十碳五烯酸5(Z),4(Z)-二烯酸和20-,21-二甲基20-HETE。优选的20-HETE拮抗剂包括5(S)-HETE,15(S)-HETE,19(S)-HETE,19-羟基十九碳五烯酸8(Z),11(Z),14(Z)-四烯酸和20-羟基二十碳6(Z),15(Z)-二烯酸。
  • 20-Hete antagonists and agonists
    申请人:MCW Research Foundation
    公开号:US06596769B2
    公开(公告)日:2003-07-22
    20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.
    本发明揭示了20-HETE激动剂和拮抗剂以及其治疗应用。在本发明的一种优选形式中,20-HETE激动剂被选择自由21-羟基十九烷-5(Z),8(Z),11(Z),14(Z)-四烯酸、20-羟基二十碳五烯-5(Z),4(Z)-二烯酸和20-,21-二甲基20-HETE的组中。优选的20-HETE拮抗剂包括5(S)-HETE、15(S)-HETE、19(S)-HETE、19-羟基十九烷-5(Z),8(Z),11(Z),14(Z)-四烯酸和20-羟基二十碳六烯-6(Z),15(Z)-二烯酸。
  • Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
    申请人:McDaniel C. Steven
    公开号:US20100210745A1
    公开(公告)日:2010-08-19
    Disclosed herein are polymeric materials such as a coating, a plastic, a laminate, a composite, an elastomer, an adhesive, or a sealant; a surface treatment such as a textile finish or a wax; a filler for such a polymeric material or a surface treatment that includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme (e.g., a lysozyme, a lytic transglycosylase) that degrades a cell wall and/or a cell membrane component, a biocidal or biostatic peotide, and/or a peptidase. Also disclosed herein are methods of altering a material's property such as service life, flexability, or rigidity, by incorporation of an enzyme into a material capable of being chemically crosslinked by the activity of a lipolytic enzyme, a hydrolase, and/or a urease.
    本文公开了一些聚合材料,如涂层、塑料、层压板、复合材料、弹性体、粘合剂或密封剂;一种表面处理,如纺织品涂层或蜡;一种填料,用于这样的聚合材料或表面处理,其中包括一种酶,如酯酶(例如,脂肪水解酶,硫酸酯水解酶,有机磷化合物降解酶),降解细胞壁和/或细胞膜成分的酶(例如,溶菌酶,裂解转糖基酶),生物杀菌或生物静态肽,以及/或肽酶。本文还公开了通过将酶纳入可通过脂肪水解酶、水解酶和/或脲酶的活性交联材料中来改变材料性能,如使用寿命、柔韧性或刚度的方法。
查看更多